Bio-Thera Secures First Global Secukinumab Biosimilar Approval

Bio-Thera Solutions has received approval from its Chinese homeland's National Medical Products Administration (NMPA) for BAT2306, a secukinumab biosimilar, making it the world's first approved biosimilar to Novartis' Cosentyx. Secukinumab is a fully human IgG1 monoclonal antibody (mAb) that selectively inhibits IL-17A, first approved in 2014 for psoriatic arthritis and now indicated across nine immune-mediated diseases including plaque psoriasis, ankylosing spondylitis, hidradenitis suppurativa and polymyalgia rheumatica, with 2025 brand sales of USD 6.668 billion, so the approval opens a large established immunology franchise to biosimilar competition.

For Bio-Thera, BAT2306 extends a biosimilar track record and captures first-mover advantage in a high-volume IL-17A market before peers catch up. According to PharmCube's NextBiopharm database, CSPC's SYS6012 and Celltrion's CT-P55 have also filed secukinumab biosimilar applications but are not yet approved. Click here to request a free trial for NextBiopharm®.

Daily News
Abbott Pays USD 40mn Upfront for Disco AND-Gated Bispecific Option
2026-11-20
MegaRobo Raises USD 200mn to Scale Physical-World AI Infrastructure
2026-11-20
Novartis Enters ADC Arena With Over USD 2bn OBI Pharma Platform Deal
2026-11-19
Pfizer Licenses Starna's In Vivo CAR-T Platform for Up to USD 2.63bn
2026-11-19
Zelgen's CD3×DLL3 Trispecific Hits Pivotal Endpoint in Relapsed SCLC
2026-11-19
Latest Report
AI- in-BD- Portfolio
Details